Why Are We Still Using Hydrochlorothiazide?

Journal of Clinical Hypertension

Volumn 13, Issue 12, 2011, Pages 867-869

  Rosendorff, Clive ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BENDROFLUMETHIAZIDE; CHLORTALIDONE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; THIAZIDE DIURETIC AGENT;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG MEGADOSE; EDITORIAL; GLUCOSE INTOLERANCE; GLYCEMIC CONTROL; HEART ARREST; HEART FAILURE; HUMAN; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; META ANALYSIS (TOPIC); POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SODIUM BLOOD LEVEL; STROKE; SYSTOLIC HYPERTENSION; UNITED STATES; URIC ACID BLOOD LEVEL;

ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS; DIURETICS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; HYPOTENSION; PHYSICIAN'S PRACTICE PATTERNS;

EID: 83055165615     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2011.00566.x     Document Type: Editorial

References (22)

1. Messerli FH, Bangalore S. Antihypertensive efficacy of aliskerin. Is hydrochlorothiazide an appropriate benchmark? Circulation. 2009;119:371-373.
2. Staffors RS, Bartholomew LK, Cushman WC, et al. Impact of the ALLHAT/JNC7 dissemination project on thiazide-type diuretic use. Arch Int Med. 2010;170:851-858.
3. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-2572.
4. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
5. Kurtz TW. Chlorthalidone: don't call it "thiazide-like" anymore. Hypertension. 2010;56:335-337.
6. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201-207.
7. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of β-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008;117:2706-2715.
8. Verdeccia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963-969.
9. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension. 1999;33:1130-1134.
10. Davey Smith G, Braccha Y, Svendsen KH, et al. Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med. 2005;142:313-322.
11. Aksnes TA, Kjeldsen SE, Rostrup M, et al. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension. 2007;50:467-473.
12. Siskovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330:1852-1857.
13. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
14. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352-358.
15. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone. Evidence supporting their interchangabiity. Hypertension. 2004;43:4-9.
16. Ernst ME, Carter BL, Zheng S, Grimm RH Jr. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone effects on systolic blood pressure and potassium. Am J Hypertens. 2010;23:440-446.
17. Woodman R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension. 2010;56:463-470.
18. Aamand R, Dalsgaart T, Jensen FB, et al. Generation of nitric oxide from nitrite by carbonic anhydrase: a possible link between metabolic activity and vasodilation. Am J Physiol Heart Circ Physiol. 2009;297:H2068-H2074.
19. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592.
20. Multiple Risk Factor Intervention Trial Research Group. Mortality after 101/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616-1628.
21. Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide; a retrospective cohort analysis. Hypertension. 2011;57:689-694.
22. Flack JM, Sica DA, Nesbitt S. Chlorthalidone versus hydrochlorothiazide as the preferred diuretic. Is there a verdict yet? Hypertension. 2011;57:665-666.